LM Advisors’s Forte Biosciences FBRX Stock Holding History

LM Advisors’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-101	Closed	-$2.08K	–	382
2023 Q4	$2.08K	Buy	+101	New	+$1.41K	﹤0.01%	659

Other funds holding FBRX

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LM Advisors's FBRX Position: Q1 2024 in Review

LM Advisors sold out of Forte Biosciences (FBRX) in Q1 2024, closing a stake of 101 shares — an estimated $2.08K sold.

LM Advisors first reported a position in FBRX in Q4 2023 and held it in 1 quarter. The position peaked at $2.08K in Q4 2023. 32 funds tracked by Wall St. Rank hold FBRX as of Q1 2024.

LM Advisors reported no remaining Forte Biosciences position as of Q1 2024 after selling out during the quarter.
LM Advisors sold 101 Forte Biosciences shares in Q1 2024, an estimated $2.08K.
LM Advisors first reported a position in Forte Biosciences in Q4 2023 and held it in 1 quarter.
LM Advisors's Forte Biosciences position peaked at $2.08K in Q4 2023.
32 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2024.

Based on LM Advisors's 13F filing for Q1 2024, filed 15 May 2024.